一分钟看懂
这是一项关于非小细胞肺癌的II 期 / III 期研究，登记的药物或干预包括EIK1001；Pembrolizumab (KEYTRUDA®)；Placebo；Paclitaxel + Carboplatin；Nab-paclitaxel + Carboplatin；Pemetrexed + Cisplatin /Carboplatin，当前状态为招募中。登记地点显示中国Daphne、Glendale、Orange、Pueblo等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
EIK1001；Pembrolizumab (KEYTRUDA®)；Placebo；Paclitaxel + Carboplatin；Nab-paclitaxel + Carboplatin；Pemetrexed + Cisplatin /Carboplatin · II 期 / III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Southern Cancer Center, P.C. · Daphne
- Los Angeles Cancer Network · Glendale
- Providence St. Joseph Hospital · Orange
- Rocky Mountain Cancer Centers, LLP · Pueblo
- Florida Clinical Trials Group · Plantation
- Florida Clinical Trials Group - Tamarac · Tamarac
- OSF Saint Francis Medical Center · Peoria
- University of New Mexico - Comprehensive Cancer Center · Albuquerque
- NYU Langone Hospital Long Island · Mineola
- NYU Langone Hospital Manhattan · New York
- Jacobi Medical Center - Albert Einstein College of Medicine · The Bronx
- White Plains Hospital · White Plains
- Tennessee Oncology · Nashville
- Blue Ridge Cancer Center · Blacksburg
- Virginia Cancer Specialists, PC · Fairfax
- Shenandoah Oncology P.C. · Winchester
- Cancer Care Northern Beaches · Frenchs Forest
- Calvary Mater Newcastle Hospital · Waratah
- Peninsula and Southeast Oncology (PASO) Medical · Frankston
- Hospital Universitario de Jerez de la Frontera · Jerez de la Frontera
- Consorci Hospitalari Provincial de Castello · Castellon
- Instituto Oncologico Dr. Rosell (IOR) · Barcelona
- Institut Catala D'Oncologia de Girona · Girona
- Hospital Quirónsalud Málaga · Málaga
公开的入选条件
- 1. Participant must be ≥ 18 years old at the time of signing the informed consent.
- 2. Participant has a life expectancy of at least 3 months.
- 3. Participant has histologically or cytologically confirmed Stage 4 NSCLC predominately squamous or non-squamous) and is considered a candidate for standard therapy with pembrolizumab and chemotherapy. Participants with NSCLC-NOS (not otherwise specified) wil
- 4. Participant must have documented evidence that mutation-directed therapy is not indicated, based on the absence of tumor-activating mutations or fusions (e.g., but not limited to EGFR, ALK, RET, ROS1, BRAF) for which approved first-line targeted therapies a
- 5. Participant has at least 1 lesion with measurable disease at Baseline according to RECIST 1.1 as determined locally. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.
- 6. Participant has not received prior systemic therapy for advanced/metastatic NSCLC.
- Note: Participants who received adjuvant or neoadjuvant treatment (after surgery and/or radiation therapy) and developed recurrent or metastatic disease more than 1 year after completing therapy are eligible.
- 7. Participant has an ECOG Performance Status of 0 to 1 assessed no more than 10 days before start of the treatment.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07365319；登记信息更新于 2026-09-17。